Published in
BioMed Central, Arthritis Research and Therapy, 1(17), p. 25, 2015
DOI: 10.1186/s13075-015-0536-2
Links
- ORCID
- BioMed Central | PDF
- [arthritis-research.com] | PDF
- [urn.kb.se] | PDF
- [urn.kb.se] | PDF
- [uu.diva-portal.org] | PDF
- [umu.diva-portal.org] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage
,
Marije K. Verheul,
Johan Rönnelid,
Ewa Berglin,
Rikard Holmdahl,
Rene Em M. Toes,
Lars Klareskog,
Leendert A. Trouw,
Solbritt Rantapää Dahlqvist,
Solbritt Rantapää-Dahlqvist
Full text: Download
Abstract
Abstract Introduction The presence of a new autoantibody system, anti-carbamylated protein (anti-CarP) antibodies, has been identified in rheumatoid arthritis (RA). The presence of anti-CarP antibodies was evaluated in samples taken from individuals who subsequently developed RA before and after onset of symptoms and related to previously analysed antibodies against citrullinated peptides (ACPA specificities) and anti-CCP2. Methods A total of 252 individuals, with 423 samples from before onset of symptoms of RA, and 197 population controls were identified as donors to the Medical Biobank of Northern Sweden; 192 of them were also sampled at the time of diagnosis. All samples were analysed for anti-CarP IgG and anti-CCP2 antibodies using ELISAs. Ten different antibody reactivities against citrullinated antigens (ACPA specificities) were analysed using a custom-made microarray based on the ImmunoCAP ISAC system (Phadia). Results The concentration of anti-CarP antibodies was significantly increased in the pre-symptomatic individuals compared with controls ( P